ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 922

Improved Incidence of Cardiovascular Disease in Patients with Incident Rheumatoid Arthritis in 2000s: A Population-Based Cohort Study

Elena Myasoedova1, John Davis 1, Veronique Roger 1, Sara Achenbach 1 and Cynthia Crowson 2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic Rochester, Rochester

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis (RA) and cardiovascular disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S108: RA – Diagnosis, Manifestations, & Outcomes II: Cardiovascular Comorbidities (921–926)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Increased burden of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) as compared to the general population is well recognized. Several studies suggested reduced CVD mortality in RA in recent decades. Longitudinal studies on trends in occurrence of CVD events in RA patients over time are lacking. To address this gap in knowledge, we evaluated trends in incidence of CVD in patients with incident RA in 1980-2009.

Methods: We studied patients with incident RA (age >18 years, 1987 ACR criteria met in 1980-2009) followed until death, migration out of the region, or 12/31/2016. Follow-up of each decade was truncated to make the length of follow-up comparable (i.e., the 1980–89 cohort was truncated at December 31, 1996, the 1990–99 cohort was truncated at December 31, 2006 and the 2000–09 cohort was truncated at December 31, 2016). Incident CVD events included myocardial infarction (MI), stroke (ischemic or hemorrhagic), coronary heart disease (CHD) death and first occurrence of any of these. Patients with CVD events prior to RA incidence date were excluded. Cox proportional hazards models were used to compare incident CVD events by decade, adjusting for age and sex. Cumulative incidence of CVD events adjusted for death from other causes was calculated.

Results: The study included 906 patients with incident RA (mean age 55.9 years; 69% female). There were 201, 299 and 406 patients in 1980-89, 1990-99 and 2000-09, respectively. During median follow-up of 10.6, 10.4 and 10.2 years per decade of RA incidence, CVD events occurred in 31, 38, and 31 patients. Patients with incident RA in 2000–09 had markedly lower cumulative incidence of any CVD events than patients diagnosed in 1990s and 1980s (Figure). Hazard ratios (HR) for any CVD events demonstrated a temporal reduction in CVD events among patients with incident RA in 2000s compared with incident RA in 1980s (HR: 0.52; 95% confidence interval (CI): 0.32-0.86) and a reduction compared with incident RA in 1990s (HR: 0.65; 95% CI: 0.40-1.05).

Conclusion: The incidence of major CVD events in RA declined markedly over time. These findings may reflect increased awareness, improved primary CVD prevention and better RA disease management in recent years. More studies are needed to understand the determinants and implications of these data.

Figure. Cumulative incidence of any CVD event in patients with RA by decade of RA incidence


Disclosure: E. Myasoedova, Pfizer, 2; J. Davis, Abbvie, 5, Pfizer, 2, 5, Sanofi Genzyme, 5; V. Roger, None; S. Achenbach, None; C. Crowson, Crescendo Bioscience, 5, Crescendo BioScience Inc., 5, Crescendo Bioscience Inc., 5, Crescendo Biosciences inc., 5, Pfizer, 2.

To cite this abstract in AMA style:

Myasoedova E, Davis J, Roger V, Achenbach S, Crowson C. Improved Incidence of Cardiovascular Disease in Patients with Incident Rheumatoid Arthritis in 2000s: A Population-Based Cohort Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/improved-incidence-of-cardiovascular-disease-in-patients-with-incident-rheumatoid-arthritis-in-2000s-a-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improved-incidence-of-cardiovascular-disease-in-patients-with-incident-rheumatoid-arthritis-in-2000s-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology